Trials / Completed
CompletedNCT00802425
Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 210 (actual)
- Sponsor
- Auris Medical AG · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine whether AM-111 is effective in the treatment of acute inner ear hearing loss (acute sensorineural hearing loss, ASNHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AM-111 | single intratympanic injection |
| DRUG | placebo | single intratympanic injection |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2012-07-01
- Completion
- 2012-10-01
- First posted
- 2008-12-04
- Last updated
- 2014-06-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00802425. Inclusion in this directory is not an endorsement.